Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of hepatic low-density lipoprotein (LDL) receptors (LDLR), thereby, decreasing hepatocyte LDL-cholesterol (LDL-C) uptake. However, it is unknown whether PCSK9 has effects on atherogenesis that are independent of lip...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Res
Main Authors: Tavori, Hagai, Giunzioni, Ilaria, Predazzi, Irene M., Plubell, Deanna, Shivinsky, Anna, Miles, Joshua, Devay, Rachel M., Liang, Hong, Rashid, Shirya, Linton, MacRae F., Fazio, Sergio
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
ORIGINAL ARTICLES
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4836631/
https://ncbi.nlm.nih.gov/pubmed/26980204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cvr/cvw053
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados